The studies identified in our SLR show that mechanisms of resistance to current NSCLC treatments, primarily osimertinib, in US populations are heterogenous and complex and pose a challenge for treating patients with EGFR-mutated a/mNSCLC. Here, EGFR is linked to non-small cell lung carcinoma.